Vaginitis
Conditions
Keywords
Aerobic vaginitis, Treatment
Brief summary
Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang Suppository 14 days group.To evaluate the efficacy and safety after treatment.
Detailed description
Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang Suppository 14 days group. Group 1: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 7 days. Group 2: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 14 days. The efficacy and safety will be evaluated 7\ 14 days after treatment and 35\ 42 days after treatment.
Interventions
DRUGExperimental: Baofukang Suppository 7 days
Experimental: Baofukang Suppository 7 days
DRUGExperimental: Baofukang Suppository 14 days
Experimental: Baofukang Suppository 14 days
Sponsors
Peking University Shenzhen Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
Aerobic vaginitis diagnosed based on present ： 1. Vaginal dischareg ; 2. pH \> 4.5; 3. Donders score≥3;
Exclusion criteria
1. Patients with other vaginitis, cervical erosion, or suspected gonorrhea, herpes simplex virus infection and other vulvar diseases; 2. Patients received systemic or vaginal antifungal or antibiotic treatment within two weeks before admission. 3. Pregnancy, lactation and intentional pregnancy; 4. Women with liver and kidney dysfunction, low immune function, diabetes, psychosis or other serious diseases; 5. Allergic constitution and patients allergic to drug ingredients in this study; 6. Those with poor compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cure rate | First week after treatment | A vaginal smear composite Donders score of 1 to 2 represents normality. A score of more than 2 is aerobic vaginitis. There are four variables(Lactobacillary; leucocytes; toxic leukocytes; parabasal cells; background flora). Detail see references Links. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side affect | First week after treatment | Number of Participants Experiencing AEs Following the First Dose of the Study Product |
Countries
China
Contacts
Primary ContactPing Liu, M.D.
Backup ContactYiheng Liang, M.D.
Outcome results
None listed